Alectinib treatment response in lung adenocarcinoma patient with novel EML4-ALK variant

被引：2

作者：

Song, Peng ^{[1
,2
]}

Zhang, Jingcheng ^{[2
,3
]}

Shang, Congcong ^{[4
]}

Zhang, Li ^{[1
,2
]}

机构：

[1] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Resp Med, 1 Shuaifuyuan, Beijing 100730, Peoples R China

[2] Peking Union Med Coll, 1 Shuaifuyuan, Beijing 100730, Peoples R China

[3] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Internal Med, Beijing, Peoples R China

[4] Henan Prov Peoples Hosp, Dept Resp Med, Zhengzhou, Henan, Peoples R China

来源：

THORACIC CANCER | 2018年 / 9卷 / 10期

关键词：

Alectinib; crizotinib; EML4-ALK; lung cancer; ALK INHIBITOR; CANCER;

D O I：

10.1111/1759-7714.12834

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Common gene fusion of the ALK gene is fusion of the ALK tyrosine kinase area and the 5'end of EML4. Seventeen EML4-ALK fusion variants have been reported. Herein, we report a novel EML4-ALK variant detected by next-generation sequencing in a 36-year-old female lung adenocarcinoma patient who experienced disease progression after six months of alectinib treatment. Second generation sequencing revealed an EML4-ALK fusion variant in which intron 19 of EML4 was fused to exon 20 of ALK. This is the first case of EML4-ALK (E19: A20) fusion to be reported. Alectinib may show unsatisfactory therapeutic effects for this kind of ALK fusion.

引用

页码：1327 / 1332

页数：6

共 50 条

[1] Identification of a EML4-ALK exon 19 fusion variant in lung adenocarcinoma and alectinib resistance
Liu, Di
Xu, Xinyan
Wen, Junmiao
Zhang, Chi
Fan, Min
[J]. LUNG CANCER, 2021, 160 : 32 - 35
[2] A novel EML4-ALK BIRC6-ALK double fusion variant in lung adenocarcinoma confers sensitivity to alectinib
Zhong, Jiang-Ming
Zhang, Gui-Feng
Lin, Li
Li, De-Yu
Liu, Zhen-Hua
[J]. LUNG CANCER, 2020, 145 : 211 - 212
[3] A Case of Lung Adenocarcinoma Response to Alectinib Harboring a Rare EML4-ALK Variant, Exon 6 of EML4 Fused to Exon 18 of ALK
Liu, Lirong
Hou, Fangfang
Liu, Yufeng
Li, Wenzhu
Zhang, Haibo
[J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2022, 20 (01): : 2 - 6
[4] Coexistence of a novel NBEA-ALK, EML4-ALK double-fusion in a lung adenocarcinoma patient and response to alectinib: A case report
Liang, Qi
Xu, Huanhuan
Liu, Yiqian
Zhang, Weiming
Sun, Chongqi
Hu, Meng
Zhu, Yizhi
Tan, Shanyue
Xu, Xian
Wang, Sumeng
Liu, Lingxiang
[J]. LUNG CANCER, 2021, 162 : 86 - 89
[5] Detection of ALK Rearrangement by Immunohistochemistry in Lung Adenocarcinoma and the Identification of a Novel EML4-ALK Variant
To, Ka-Fai
Tong, Joanna H. M.
Yeung, King S. F.
Lung, Raymond W. M.
Law, Peggy P. Y.
Chau, Shuk Ling
Kang, Wei
Tong, Carol Y. K.
Chow, Chit
Chan, Anthony W. H.
Leung, Linda K. S.
Mok, Tony S. K.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (07) : 883 - 891
[6] Identification of a Novel EML4-ALK Fusion Transcript in Lung Adenocarcinoma
To, K.
Tong, J. H. M.
Law, P. P. Y.
Chau, S. L.
Lung, R. W. M.
Yeung, S. F.
Kang, W.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (09) : S218 - S219
[7] Coexistence of a Novel PRKCB-ALK, EML4-ALK Double-Fusion in a Lung Adenocarcinoma Patient and Response to Crizotinib
Luo, Jing
Gu, Dejian
Lu, Huasong
Liu, Si
Kong, Jinliang
[J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (12) : E266 - E268
[8] Response to erlotinib in a patient with lung adenocarcinoma harbouring the EML4-ALK translocation: A case report
Ali, Greta
Chella, Antonio
Lupi, Cristiana
Proietti, Agnese
Niccoli, Cristina
Boldrini, Laura
Davini, Federico
Mussi, Alfredo
Fontanini, Gabriella
[J]. ONCOLOGY LETTERS, 2015, 9 (04) : 1537 - 1540
[9] Response to Crizotinib in a Lung Adenocarcinoma Patient Harbouring EML4-ALK Transtocation with Adnexal Metastasis
Wang, Wenxian
Jin, Ying
Zhang, Yiping
[J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1176 - S1176
[10] Coexistence of a Novel NBAS-ALK, EML4-ALK Double-Fusion in a Lung Adenocarcinoma Patient With LM and Response to Ensartinib
Xu, X.
Li, N.
Fan, Y.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S445 - S445

← 1 2 3 4 5 →